Navigation Links
Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008

WEIFANG, Shandong Province, China, Feb. 14 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today reported financial results for the three months ended December 31, 2007.

Second Quarter of Fiscal 2008 Highlights

-- Net sales increased 102.7% to $25.0 million

-- Gross profit rose 91% to $5.9 million

-- Gross profit margin was 23.5%

-- Operating income increased 121.2% to $4.1 million

-- Net income increased 97% to $3.1 million

-- Weighted avg. diluted shares outstanding were 20.3 million vs. 10.1


-- Fully diluted EPS was $0.15 versus $0.16

Second Quarter of Fiscal 2008 Results

For the second quarter of fiscal 2008, net revenues increased 102.7% to $25.0 million from $12.3 million for the second quarter of fiscal 2007. This increase was largely due to more cornstarch production, higher product prices, diversification of product lines and the expansion of higher-value products. The Company raised the sales of cornstarch, which constituted a higher proportion of total sales revenue compared to the same reporting period last year. Although cornstarch had a lower gross profit margin, the Company nevertheless increased its production to generate necessary working capital and funds for construction of its new glucose complex.

In addition to its pharmaceutical glucose series of products and cornstarch, the Company also produced significant amounts of other non- medicinal glucose or cornstarch related products. The sales revenues generated from these products were approximately 5.9 times of those the same period last year, and constituted approximately 26.6% of its total sales revenues for the six months ended December 31, 2007.

"We continued to see strong growth in second quarter ofUNAUDITED)

2007 2006



Net income $ 5,382,096 $ 3,073,002

Adjustments to reconcile

net income to cash

provided by operating


Depreciation 1,187,166 802,766

Amortization 23,820 21,159

Allowance for bad debts (126,334) 718

Gain on equipment

disposal (90,098) --

Loss on disposal of

land use right 5,954 --

Earnings on equity

investment (149,757) (22,207)

Change in operating

assets and liabilities:

Accounts receivable (185,355) (1,042,970)

Notes receivable (772,571) (569,932)

Other receivables 1,186,223 (975)

Other receivables -

related party 2,531,257 (502,261)

Other receivables -

shareholder 1,254,248 --

Inventories 159,692 (393,469)

Prepayments (472,365) (139,392)

Prepayments - related

party -- (39,024)

Accounts payable (1,668,080) 896,568

Accounts payable -

related party (293,176) (412,070)

Accrued liabilities (150,906) 43,689

Other payable (313,162) 299,581

Customer deposit 417,062 398,934

Payable - officer 31,145

Taxes payable 1,671,334 33,746

Net cash provided by

operating activities 9,628,193 2,447,863


Acquisition of equity

investment -- (898,150)

Purchase plant and

equipment (28,455) (415,524)

Proceeds from equipment

disposal 34,733

Additions to construction

in progress (5,865,225) (7,553,156)

Acquisition of land use

right (317,183) (10,677)

Purchase of software

program (5,343) --

Advances on plant and

equipment purchase (5,226,396) --

Loan repayment from

related party 667,950

Loan to related party -

non-current -- (723,205)

Net cash used in

investing activities (10,739,919) (9,600,712)


Decrease in restricted

cash 3,842,060 28,071

Borrowings on notes

payable - banks 1,335,900 7,055,930

Payments on notes payable

- banks (9,084,120) (7,084,000)

Borrowings on short term

loans 3,566,853 13,168,650

Payments on short term

loans (7,440,963) (4,946,150)

Borrowings on employee

loans 1,271,112 --

Payments on employee

loans (137,616) --

Borrowings on third party

loan 1,781,556 --

Payments on long term

loans -- (885,500)

Cash proceeds from

issuance of common stock 506,493 --

Dividend paid to

shareholders -- (393,257)

Net cash (used in)

provided by

financing activities (4,358,725) 6,943,744


CHANGE IN CASH 96,016 9,228

DECREASE IN CASH (5,374,435) (199,877)

CASH, beginning of period 6,420,439 502,457

CASH, end of period $ 1,046,004 $ 302,580

For more information, please contact:

Company Contact:

Mr. Yizhao Zhang


Shengtai Pharmaceutical, Inc.

Tel: +86-536-629-5728


Investor Relations Contact:

Mr. Crocker Coulson


CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY Office)


fiscal 2008," said Chairman and CEO, Mr. Qingtai Liu. "Our revenues and net income kept growing dramatically during this quarter due to higher glucose product prices, increased cornstarch production and sales, improved sales of higher value products and the benefits from our vertically integrated production line. We believe that through manufacturing innovative products to meet market demand, we would be able to command better profit margins, diversify our product lines and minimize our operating risks."

Gross profit for the three months ended December 31, 2007 was $5.9 million, an increase of 91% from $3.1 million for the same period of the prior year. Gross margin for the second quarter of fiscal 2008 was 23.5%. The increased gross profit was mostly due to economies of scale resulting from the expansion of production output and enhanced operating efficiencies. Although product cost increased as a result of commodity price increases and other raw material price increases, the selling price was higher than the price increase of raw materials, thus making its gross profit higher.

Selling, general and administrative expenses for the three months ended December 31, 2007 were $1.8 million, an increase of $0.9 million, or 89.4% compared with the corresponding period in 2006. The increase in selling, general and administrative expenses was the result of the increase of our production output, expansion of the Company's domestic sales network and increased shipping costs due to higher sales of cornstarch.

Shengtai Pharmaceutical's operating income in the three months ended December 31, 2007 increased 121.2% to $4.1 million from $1.8 million in the prior year, while the operating margin increased to 16.2% from 14.9%.

Net income for the three months ended December 31, 2007 was $3.1 million, an increase of $1.5 million, or 97% compared with the corresponding period in 2006. The increase in net income was due to an increase in our product prices, sales volume and the introduction of new products. Weighted average diluted earnings per share were $0.15 for the three months ended December 31, 2007, compared to $0.16 for the three months ended December 31, 2006. The higher share count in the second fiscal quarter of 2008 was due to a private placement of stock in May 2007.

Financial Condition

As of December 31, 2007, Shengtai Pharmaceutical had cash and restricted cash of $2.9 million and working deficit of $14.7 million. During the three months ended December 31, 2007, the Company generated $9.6 million in cash flow from operations. As of December 31, 2007, the Company had $36.2 million in total debt, and $38.9 million of shareholders' equity.

Business Outlook

Shengtai Pharmaceutical's new cornstarch production facility, with a maximum production capacity of 240,000 metric tons per year, was completed at the end of October 2007. With these cornstarch production facilities, which are close to the Company's existing glucose production plant and new glucose production complex, the Company is able to ensure the adequacy and quality of the cornstarch as the main component of pharmaceutical glucose and lower shipping costs to improve its profit margins.

After acquiring the rights to use 85,880 square meters of new land in Changle Economic and Technology Development Zone in April 2007, Shengtai Pharmaceutical set out to build a new glucose production complex with an expected production capacity of 120,000 tons per year. The new facility will be equipped with state-of-the-art machinery and technology, and the Company will apply international quality control standards over the production. The new construction commenced in early July 2007 and is expected to be complete in the first half of calendar year 2008.

Shengtai Pharmaceutical continued to strengthen its domestic sales network through the establishment of four representative offices in Chengdu, Guangzhou, Hangzhou and Nanchang. However, international sales may be impacted somewhat due to more strict government policies to discourage food and natural resources processing exports, and the appreciation of the Renminbi against the U.S. dollar.

"By identifying and pursuing innovative products and technology, we intend to improve our cost structure, increase our market share, command better profit margins and reduce our operating risks," commented Mr. Zhang, the Company's Chief Financial Officer, "After we upgrade our existing facilities and complete the new glucose production complex in the first half of 2008, we will shift excess cornstarch to be utilized internally for pharmaceutical glucose production and other higher value-added products, which should further increase our profitability."

"We project that for the fiscal year ending June 30, 2008 we will achieve an after-tax net income of at least $9,000,000 or fully diluted earnings per share of at least $0.43," said Mr. Zhang.

Teleconference Information

A conference call will take place at 9:00 a.m. Eastern (U.S.) time on Friday, February 15, 2008. Anyone interested in participating should call 866- 800-8648 if calling from within the United States, or 617-614-2702 if calling internationally; the passcode is 835 628 35.

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Friday, February 15 at 11:00 a.m. Eastern Time. To listen to the playback, please call 888-286-8010 if calling within the United States, or 617-801-6888 if calling internationally. Please use passcode 497 603 34 for the replay.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of glucose products, which include pharmaceutical grade glucose used for medical purposes, and glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc. please visit .

Forward-looking Statements

Certain statements in this press release and oral statements made by the Company, constitute forward-looking statements. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the Company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

--Financial Tables Follow--



AS OF DECEMBER 31, 2007 AND JUNE 30, 2007


December 31, June 30,

2007 2007



Cash $ 1,046,004 $ 6,420,439

Restricted cash 1,885,500 5,628,500

Accounts receivable, net

of allowance for doubtful

accounts of $319,887

and $431,178 as of

December 31, and June 30,

2007, respectively 6,345,988 5,779,967

Notes receivable 1,799,285 984,675

Other receivables 2,155,536 3,484,484

Other receivables -

related parties -- 2,491,656

Other receivables -

shareholder -- 1,229,625

Loan to related party -- 657,500

Inventories 4,474,855 4,449,267

Prepayments 631,130 140,376

Total current assets 18,338,298 31,266,489

PLANT AND EQUIPMENT, net 38,350,904 30,178,074


Investment in Changle

Shengshi Redian Co., Ltd. 3,188,822 2,675,678

Loan to related party -

non-current 411,300 394,500

Prepayments - non-current 12,640,708 7,429,371

Intangible assets - land use right,

net of accumulated amortization 2,193,801 1,816,021

Total other assets 18,434,631 12,315,570

Total assets $ 75,123,833 $ 73,760,133

L I A B I L I T I E S A N D S H A R E H O L D E R S' E Q U I T Y


Accounts payable $ 3,408,140 $ 3,807,997

Accounts payable - related

party 935,077 949,992

Notes payable - banks 1,371,000 8,942,000

Short term loans 15,697,950 18,870,250

Accrued liabilities 164,386 229,643

Other payable 1,937,205 1,526,903

Employee loans 1,785,196 596,516

Employee loan - officer 36,963 --

Third party loan 2,160,193 318,274

Customer deposit 1,258,155 796,228

Long term loan - current maturity 397,590 381,350

Taxes payable 3,856,304 2,048,932

Total current liabilities 33,008,159 38,468,085


Other payable - noncurrent 3,183,858 3,661,472

Total long term liabilities 3,183,858 3,661,472

Total liabilities 36,192,017 42,129,557



Preferred stock, $0.001

par value, 5,000,000

shares authorized,

no shares issued and

outstanding -- --

Common stock, $0.001 par

value, 100,000,000 shares

authorized, 19,069,805 and

18,875,000 shares issued and

outstanding as of

December 31, and June 30,

2007, respectively 19,070 18,875

Paid-in capital 19,669,847 19,163,549

Statutory reserves 1,735,484 1,735,484

Retained earnings 15,267,766 9,885,670

Accumulated other

comprehensive income 2,239,649 826,998

Total shareholders' equity 38,931,816 31,630,576

Total liabilities and

shareholders' equity $ 75,123,833 $ 73,760,133





Three months ended Six months ended

December 31, December 31,

2007 2006 2007 2006

SALES REVENUE $ 24,954,288 $ 12,310,489 $ 44,327,357 $ 22,909,810

COST OF SALES 19,086,274 9,237,442 33,865,306 17,397,319

GROSS PROFIT 5,868,014 3,073,047 10,462,051 5,512,491



EXPENSES 1,814,376 958,077 3,510,931 1,929,945


OPERATIONS 4,053,638 2,114,970 6,951,120 3,582,546



Earnings on

equity investment 977 17,683 149,756 22,207


income 69,962 38,369 109,709 97,163


expense (26,495) (2,783) (203,844) (2,783)


expense and other

charges (519,417) (351,223) (935,881) (368,638)

Interest income 32,243 15,678 98,404 43,645

Other (expense),

net (442,730) (282,276) (781,856) (208,406)



INCOME TAXES 3,610,908 1,832,694 6,169,264 3,374,140


INCOME TAXES 481,323 243,723 787,168 301,138

NET INCOME 3,129,585 1,588,971 5,382,096 3,073,002




Foreign currency


adjustments 140,556 246,971 1,412,651 246,971


INCOME $ 3,270,141 $ 1,835,942 $ 6,794,747 $ 3,319,973



Basic $ 0.17 $ 0.16 $ 0.28 $ 0.30

Diluted $ 0.15 $ 0.16 $ 0.27 $ 0.30



Basic 18,961,992 10,125,000 18,918,496 10,125,000

Diluted 20,296,006 10,125,000 20,000,956 10,125,000





SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
2. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
6. BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynchs Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... enhanced Pepper Flow promotional review platform at the Promotional Review Committee Compliance ... capabilities help marketers streamline the medical, legal, and regulatory review (MLR) process ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: